New Human Biomarker Findings Support Mechanism of Action of Kerendia® (finerenone) in Patients with Chronic Kidney Disease Associated with Type 2 Diabetes
WHIPPANY, N.J.--(BUSINESS WIRE)--Nov 2, 2023--At the American Society of NephrologyÄ¢¹½ÊÓÆµ (ASN) Kidney Week 2023, Bayer today announced pharmacodynamic data on Kerendia ® (finerenone), the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate dual cardiorenal ...

